Form 8-K - Current report:
SEC Accession No. 0001725160-25-000006
Filing Date
2025-01-28
Accepted
2025-01-28 16:07:25
Documents
16
Period of Report
2025-01-22
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20250122.htm   iXBRL 8-K 41219
2 EX-99.1 rifpr01282025-forworkivax.htm EX-99.1 17090
7 image_0a.jpg GRAPHIC 68307
  Complete submission text file 0001725160-25-000006.txt   302042

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20250122.xsd EX-101.SCH 2039
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20250122_def.xml EX-101.DEF 4069
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20250122_lab.xml EX-101.LAB 27067
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20250122_pre.xml EX-101.PRE 16301
18 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20250122_htm.xml XML 2835
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 25564187
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)